Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast
The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D brands like the dipeptidyl peptidase-IV (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists will exert downward pressure on market sales. Nonetheless, the launch of Eli Lilly’s first-in-class, glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist, Mounjaro, and other late-phase emerging therapies will further support the T2D market through 2032. Although the marketed therapies help maintain HbA1c levels, there is a significant unmet need for disease-modifying therapies that can offer a better quality of life and reduce the treatment burden of intensive combination therapy.
Questions answered
- What are the drivers and constraints in the T2D market, and how will the market evolve over the forecast period?
- How has the launch of Eli Lilly’s tirzepatide (Mounjaro) affected the prescribing of GLP-1 receptor agonists such as Eli Lilly’s Trulicity and Novo Nordisk’s Ozempic in the United States? How will the therapy be received in the European market?
- How will the launch of nonbranded therapies affect the T2D market?
- What do key opinion leaders think about emerging therapies such as Novo Nordisk’s insulin icodec and CagriSema?
Content highlights
Geographies: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: prevalence of T2D by country with population-specific diagnosed and drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2032, segmented by brands / generics.
Emerging therapies: Phase 3/PR: 5 drugs; coverage of select preclinical, Phase 1, and Phase 2 products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for type 2 diabetes
- Current treatments used for type 2 diabetes
- Market events impacting the use of key current therapies in type 2 diabetes
- DPP-IV inhibitors
- GLP-1 receptor agonists
- GIP / GLP-1 receptor agonists
- SGLT-2 inhibitors
- Biguanides
- Sulfonylureas
- Thiazolidinediones
- Insulin analogues
- Long-acting insulin + GLP-1 receptor agonist FDCs
- AMP-activated protein kinase stimulators
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for type 2 diabetes
- Estimated launch dates of key emerging therapies for the treatment of type 2 diabetes
- GLP-1 receptor agonists
- GIP / GLP-1 / glucagon receptor agonist
- Long-acting insulin analogues
- Long-acting insulin + GLP-1 receptor agonist FDCs
- Amylin analogue + GLP-1 receptor agonist FDCs
- Early-phase pipeline analysis
- Key discontinuations and failures in type 2 diabetes
- Key findings
- Access & Reimbursement Overview
- Methodology
- Appendix
Shambhavi Shukla, M.Tech., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematology. Ms. Shukla has authored competitive landscape and market insight reports on type 1 and type 2 diabetes, osteoporosis, and FSGS. Before joining Clarivate, she was with Evalueserve, where she worked closely with top pharmaceutical companies, helping them with commercial and technical ad-hoc requests. She holds a master’s degree in biotechnology from Amity University in India.
Ansuman Swain, B.D.S., M.P.H., Epidemiologist, Epidemiology. As part of his M.P.H. curriculum, he worked as an intern at the National Health Mission in Odisha, India, where he observed the implementation of the RBSK program. Mr. Swain is a graduate in dentistry from KIIT University in Odisha and holds an M.P.H. degree from Manipal Academy of Higher Education in Karnataka, India, with a specialization in global health from Maastricht University in the Netherlands.